Patients with severe asthma represent a minority of the total asthma population, but carry a majority of the morbidity and healthcare costs. Achieving better asthma control in this group of patients is therefore of key importance. Systematic assessment of patients with possible severe asthma to identify treatment barriers and triggers of asthma symptoms, including co-morbidities, improves asthma control and reduces healthcare costs and is recommended by international guidelines on management of severe asthma. This review provides the clinician with an overview of the prevalence and clinical impact of the most common co-morbidities in severe asthma, including chronic rhinosinusitis, nasal polyposis, allergic rhinitis, dysfunctional breathing, vocal cord dysfunction, anxiety and depression, obesity, obstructive sleep apnoea syndrome (OSAS), gastroesophageal reflux disease (GERD), bronchiectasis, allergic bronchopulmonary aspergillosis (ABPA) and eosinophilic granulomatous with polyangiitis (EGPA). Furthermore, the review offers a summary of recommended diagnostic and management approaches for each co-morbidity. Finally, the review links co-morbid conditions to specific phenotypes of severe asthma, in order to guide the clinician on which co-morbidities to look for in specific patients.
INTRODUCTION
The burden of disease is high in severe asthma; although a minor proportion of asthma patients have severe asthma, 1 they carry the majority of morbidity and healthcare utilization. 2 Severe asthma patients have frequent exacerbations and hospitalizations, as well as more absence from work and overall impart much higher healthcare costs than patients with mild to moderate asthma. 2 Achieving good asthma control on a minimum of anti-asthmatic medications is the goal in all asthma patients, 3 but may be particularly difficult to reach in severe asthma. In a nationwide study of severe asthma in Denmark, approximately one-third of patients treated for severe asthma had poorly controlled disease, despite being prescribed high doses of anti-asthmatic medications. 1 Interestingly, only one-third of patients with poorly controlled severe asthma had seen a specialist within the previous 12 months. 1 Systematic assessment of difficult asthma in a specialist severe asthma clinic improves asthma-related outcomes such as exacerbations and reduces healthcare utilization. 5 It is therefore recommended in all patients with possible severe asthma by the ERS/ATS guidelines on severe asthma. 1 A key component in systematic assessment of severe asthma is the identification and management of factors that aggravate asthma symptoms and worsen asthma control, such as co-morbidities.
Co-morbidities are important in the management of severe asthma, as they may contribute to poor disease control by aggravating symptoms, as well as mimicking symptoms. This may in turn lead to overtreatment with anti-asthmatic medications. Overall, co-morbidities increase costs associated with treating severe asthma. 6 Co-morbidities may furthermore be the result of side effects of the treatment of severe asthma (iatrogenic co-morbidities) and should be recognized as such to avoid treatment-induced harm to the patient. 7 Iatrogenic co-morbidities are typically related to the use of systemic steroids, and include obesity, osteoporosis, depression and gastroesophageal reflux disease (GERD). 7 Asthma is a heterogeneous disease, 8 and some comorbidities may be more common in specific phenotypes of severe asthma, which may guide the diagnostic assessment strategy in difficult asthma, although the evidence in this area is still limited.
Understanding the cause-and-effect relationships between severe asthma and specific co-morbidities is important in order to predict the impact of specific interventions. As well as recognizing aetiological co-morbidity, that is caused by a single factor, such as obesity affecting both asthma, GERD and OSAS (Fig. 1) .
Importantly, the diagnosis of co-morbidities is an important part of the systematic assessment of patients with potentially severe asthma. The aim of systematic assessment is being to differentiate between true severe refractory asthma, and patients with difficult-to-control asthma, in whom symptoms are driven by factors other than asthma, such as co-morbidities.
This review provides the clinician with an overview of the prevalence and clinical impact of the most common co-morbidities in severe asthma, including chronic rhinosinusitis (CRS), nasal polyposis, allergic rhinitis, dysfunctional breathing (DB), vocal cord dysfunction (VCD), anxiety and depression, obesity, obstructive sleep apnoea syndrome (OSAS), GERD, bronchiectasis, allergic bronchopulmonary aspergillosis (ABPA) and eosinophilic granulomatous with polyangiitis (EGPA) ( Table 1) . Furthermore, the review summarizes recommended diagnostic and management approaches. Finally, the review links co-morbid conditions to specific phenotypes of severe asthma, in order to guide the clinician on which co-morbidities to look for in specific patients.
CRS AND NASAL POLYPS
CRS is defined as an inflammatory condition in the nose and paranasal sinuses, characterized by nasal blockage or nasal discharge, in combination with facial pain/pressure or loss of smell, present for a period of at least 12 weeks. 9 Among severe asthma patients approximately 50% are reported to have CRS. 10 CRS seems to be a marker of severe asthma per se. There is a correlation between the level of inflammation in the upper and lower airways of patients with CRS and severe asthma, 11 but it is unclear to what extent CRS is a coexisting condition and to what extent it affects lower airways, for example via postnasal drip.
Patients with difficult asthma and CRS report more symptoms, particularly of sputum and cough, 12 and have an increased risk of asthma exacerbations. 12 CRS Figure 1 Co-morbidities in severe asthma: possible cause-and-effect relationships. ABPA, allergic bronchopulmonary aspergillosis; CRSsNP, chronic rhinosinusitis (CRS) without nasal polyps; CRSwNP, CRS with nasal polyps; GERD, gastroesophageal reflux disease; OSAS, obstructive sleep apnoea syndrome.
with nasal polyps (CRSwNP) in particular is a feature of severe asthma, 13 typically associated with late-onset eosinophilic asthma (Table 2). 14 These patients may also have intolerance to aspirin (ASA) 15 (Samters Triad), which may provoke asthma and rhinitis symptoms, and are clinically characterized by frequent exacerbations with an increased reliance on oral corticosteroids. Intolerance to ASA has more recently been termed 'Non-steroidal anti-inflammatory drugsexacerbated respiratory disease' (NERD), as the patient may also respond to other NSAIDs such as ibuprofen.
Treatment of CRS is aimed at reducing airway inflammation, and nasal steroids are the first-line treatment, 9, 16 which may be combined with nasal lavage. 17 However, other medical interventions such as montelukast 18 and low-dose macrolides 19 may also have some effect, although at present there remains the need for large, randomized trials of these treatments.
Surgical treatment (endoscopic sinus surgery (ESS)) may be indicated in patients with severe nasal polyposis, and has been shown to improve asthma control in patients with ASA intolerance. 20 However, patients with nasal polyps tend to relapse 21 and there is a need for better treatments for this group of patients, who may benefit from monoclonal antibodies targeting eosinophils.
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ALLERGIC RHINITIS
Although allergic sensitization is common in severe asthma, allergy seems to play less of a role in severe asthma in general, compared with milder asthma 12 and as such is not a co-morbidity that is specific for severe asthma. The majority of patients with severe asthma have allergic sensitization to aeroallergens, 10, 23 but only approximately 30% use regular anti-allergic medications such as nasal steroids. 1 However, early onset of severe asthma is typically associated with allergic sensitization and allergic rhinoconjuctivitis (Table 2) . 23, 24 Patients with early-onset allergic asthma tend to have a clear association between allergen exposure and symptoms, 25 as well as between upper and lower airway symptoms. 26 Whereas in late-onset severe asthma, patients may frequently have allergic sensitization to aeroallergens, but in most cases their symptoms do not seem to be aggravated by allergen exposure or associated with symptoms of allergic rhinitis. [26] [27] [28] Patients with allergic rhinitis report poorer asthma control, more exacerbations and emergency visits 29 and have more difficulty achieving symptom control. 30 Treating coexisting allergic rhinitis improves asthma control and reduces healthcare resource utilization. 31, 32 Allergic rhinitis in severe asthma is treated similarly to mild or moderate asthma, with nasal steroids as first choice in patients with persistent symptoms, 31 possibly combined with local and systemic anti-histamines, depending on the severity of symptoms. 31, 33 Antileukotrienes should also be considered as an antiasthma treatment targeting both upper and lower airways, in patients with severe asthma and allergic rhinitis. 31, 34 Anti-IgE treatment may be considered in patients with severe asthma who are sensitized to perennial aeroallergens 35, 36 and patients with symptoms of 
DYSFUNCTIONAL BREATHING
DB may be defined as 'chronic changes in breathing pattern that result in dyspnoea and other symptoms, in the absence or in excess of the magnitude of physiological respiratory or cardiac disease'. 38 DB is a heterogeneous condition, with a range of underlying subtypes. Some patients have chronic hyperventilation with associated respiratory alkalosis or hypocapnia driving their symptoms. 38 Others have an abnormal breathing pattern, without alterations in their gas exchange, for example apical breathing (thoracic dominant), which results in excessive dyspnoea. 38 DB is characterized by a combination of respiratory and general symptoms. Patients typically report symptoms of intense dyspnoea in relation to even mild physical activity and being unable to take a satisfying breath, but also may report dizziness, tightness or tingling around mouth, fingers and toes, lack of concentration, feelings of exhaustion and anxiety. Patients report air hunger and may tend to yawn or sigh repeatedly, as they feel it alleviates their symptoms briefly, and they will often feel that it is difficult to breathe through the nose. 38 Both of these phenomena reflect the increased minute volume of these patients.
DB is common in difficult asthma, with prevalence rates from 19% to 52%, depending on the population. 12, 24 In a cluster analysis of asthma patients from secondary care, DB was the most common among patients with obese, non-eosinophilic asthma (52%) and least common in late-onset eosinophilic asthma (19%) ( Table 2 ). 14 DB may mimic asthma symptoms, leading to a risk of overtreatment. Patients with DB report poorer asthma control 30 and their anti-asthmatic medications may be inappropriately increased if the contribution of DB to their symptoms is not recognized. There is no gold standard for diagnosing DB. The Nijmegen questionnaire may be used to screen for symptoms of DB 39 ; this questionnaire is the most widely used, despite originally being validated in patients with exercise-induced hyperventilation. Exercise testing may be used to assess the pattern of breathing and levels of carbon dioxide during activity 40 ; however, no gold standards for identifying DB during exercise have been defined.
Hyperventilation testing has been used to diagnose DB, by assessing symptoms provoked by voluntary hyperventilation. However, this test is no longer regarded as a gold standard for diagnosing DB, as a double-blinded study, using eucapnic hyperventilation via a face mask as a placebo, demonstrated a very high proportion of false-positive tests, indicating that hypocapnia was not the likely trigger of symptoms. 41 Breathing retraining with a physiotherapist may be used to manage DB. Studies on the effect in asthma are small and heterogeneous, but have shown some effect on symptoms, although little if any effect on objective parameters such as lung function. 42, 43 The effect of breathing retraining in difficult asthma has not been reported, but individual patients may benefit from breathing retraining and access to physiotherapists with expertise in the field seems mandatory in a severe asthma clinic.
VOCAL CORD DYSFUNCTION
VCD is defined as 'a paradoxical movement of the vocal cords'; a hyperfunctional laryngeal reflex which results in adduction of the vocal cords with resultant airflow limitation. 44 Patients may experience throat tightness (globus sensation), stridor and hoarseness, but also wheezing, dyspnoea and cough; symptoms which may be inseparable from asthma symptoms. 44 VCD is a mimic of asthma symptoms, and may affect asthma control by misattribution of VCD-related symptoms. VCD may mimic severe, steroid refractory asthma in particular, as VCD patients may be misinterpreted as having asthma with high rates of 'exacerbations' and emergency visits with minimal clinical response to oral corticosteroids. 45 The prevalence of VCD has been reported to be as high as 32-50% among patients with difficult asthma, 12, 46 but overall little is known about the true prevalence of VCD in severe asthma as most studies have examined selected patient groups.
In patients who primarily report exercise-related symptoms, the cause of laryngeal obstruction is more commonly located above the vocal cords. Exerciseinduced laryngeal obstruction (EILO) is a phenomenon of rapid swelling of the aryepiglottic folds during peak exercise, which disappears shortly after the cessation of physical activity. 47 Hence, the diagnosis of EILO requires continuous laryngoscopy during exercise (CLE), typically on a treadmill. 48 The prevalence of EILO in severe asthma has not been described. Furthermore, the mechanisms and triggers underlying EILO are unclear, as is the association with VCD.
Potential triggers of VCD are the conditions that lead to increased laryngeal sensitivity such as postnasal drip 49 and gastroesophageal reflux, 50 as well as respiratory infections. 51 However, a large proportion of patients appear to have a functional component, with pathopsychological traits such as signs of conversion disorder. 52, 53 Asthma patients with VCD report poorer asthma control. Overall, asthma patients with coexisting VCD report more exacerbations, are hospitalized more frequently and use more anti-asthmatic medications including oral prednisolone. 45 The gold standard for diagnosing VCD is the demonstration of paradoxical vocal cord movement while the patient is wheezing or stridulous. 44 VCD may be difficult to diagnose as a laryngeal examination will be normal outside attacks, as will inspiratory flows on the flow-volume loop. During an attack, patients may demonstrate a pattern of extrathoracic flow limitation (truncated inspiratory loop), however, spirometry appears to have a low predictive value for detecting VCD. 54 Challenge laryngoscopy where patients are provoked by triggers such as perfume may be used; however, there is currently no agreed test protocol. 47 Symptom-based assessment appears to have limited usefulness in predicting the presence of VCD in asthma. While some patients have stridor and hoarseness, the majority have symptoms that cannot be differentiated from asthma symptoms such as shortness of breath and wheezing. 55 However, symptom screening may be helpful in determining whether a laryngoscopy is required. The Pittsburgh VCD Index is a simple four-question questionnaire which has been shown to have an acceptable sensitivity (0.83) and specificity (0.95) in detecting VCD. 56 Hence, objective testing is required in patients with classic VCD symptoms, but should also be considered more generally in patients not responding well to treatment of their asthma.
Identification and treatment of potential triggers is important in the management of VCD. Nasal steroids may improve signs of VCD in patients with chronic rhinitis 49 and patients with gastroesophageal reflux may benefit from acid suppression. 57 However, overall, the evidence on the effect of treating these conditions is sparse and mainly empirical.
Speech therapy aims to teach patients how to relax their vocal cords through various exercises. Although systematic evidence on the effect of speech therapy in asthma is lacking, 58 it may be helpful in some patients, and access to speech therapists or physiotherapists with experience in VCD is an important part of the management of severe asthma.
Psychological interventions in VCD have only been examined in case series, and there is a need for prospective, randomized studies to clarify the clinical efficacy of these interventions.
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ANXIETY AND DEPRESSION
A significant proportion of patients with difficult asthma report symptoms of anxiety and depression, 1, 24 although it is unclear to which extent these symptoms are the result of the severity of their asthma, or a contributing cause of their symptoms. In the Severe Asthma Research Population (SARP), patients with insomnia, anxiety and depression had a 2.4-fold increased risk for poor asthma control and a 1.5 higher risk for healthcare utilization, suggestion a significant impact of these conditions on asthma-related outcomes. 59 A commonly used tool for assessing potential traits of anxiety and depression is the Hospital Anxiety and Depression Scale (HADS), a validated self-assessment questionnaire containing 14 questions in total, 7 for anxiety and 7 for depression. 60, 61 The highest score is 21 for each domain. A score of 8 or above has been reported to detect cases of anxiety and depression with a sensitivity and specificity of approximately 80% for both. 67 Anxiety is more frequently reported by patients with late-onset non-eosinophilic asthma, compared with other phenotypes of severe asthma, whereas depression is more prominent in patients with early-onset allergic asthma 24 (Table 2 ). This dissociation suggests differences in the causality relationships between severe asthma, and anxiety and depression. For example, it may be speculated that patients with a life-long severe asthma might be more likely to develop a depression. Whereas anxiety might conversely be a contributor to symptoms in late-onset non-eosinophilic asthma, a phenotype of asthma also appears to be more frequently associated with DB 24 (Table 2) . Although there is some evidence to suggest that psychoeducational interventions may reduce the hospitalization rate in severe adult asthma, the size and quality of studies are insufficient to make firm conclusions on the overall efficacy of these interventions. assessment and management of this patient group is a clear advantage in a severe asthma clinic.
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OBESITY
Obese patients with severe asthma report more asthma symptoms and lower lung function, and tend to have more asthma exacerbations, as well as a higher use of oral steroids. 63, 70, 71 Conversely, obesity is one of the comorbidities of severe asthma that may be related to the side effects of treatment, that is systemic steroids, 7 thus creating a potential vicious circle of weight gain leading to increased symptoms and in turn an up-titration of steroids.
The mechanisms linking obesity to asthma severity are unclear, but may include physiological factors such as airway closure and lung restriction, but also underlying immunological factors, as well as dietary factors. 72 Obese asthma patients have more airway neutrophilia, which correlates to systemic saturated fatty acid levels. 73 Intake of a meal with a high content of saturated fat induces airway neutrophilia 74 and conversely weight loss has been shown to reduce airway neutrophils. 73 These differences in pathogenetic mechanisms may explain the reduced steroid responsiveness observed in obese asthma patients. 75 Obesity is a feature of late-onset non-eosinophilic asthma 24 (Table 2) , although the SARP study also identified a group of predominantly females with severe late-onset asthma, obesity and increased sputum eosinophils, and obesity in general has been linked to higher levels of airway IL-5 and eosinophils. 23, 76 Hence, obesity may be linked to both non-eosinophilic (neutrophilic) asthma and eosinophilic asthma.
Obesity is furthermore a risk factor for other comorbidities that may aggravate asthma symptoms, such as OSAS 70 and GERD. 71 In severe asthma, both overweight and obesity increase the risk of obstructive sleep apnoea, with reported prevalence rates of 16.7% in the obese (BMI > 30) and 2.8% in the overweight (BMI = 25-30) versus 0% in normal weight patients. 70 Furthermore, obese asthma patients frequently have symptoms of DB. 24 Finally, obesity is linked to the metabolic syndrome, which may have a potential role in driving inflammation in obese patients with severe asthma. 77, 78 Weight reduction may improve symptom control, 79 but also objective parameters such as lung function, small airways dysfunction and airway hyperresponsiveness. 80, 81 Even a moderate weight loss of approximately 5-10% appears to be sufficient to achieve significant clinical improvements in asthma control. 82 Hence, obese patients with severe asthma should be offered advice on weight loss, if possible by a dietician, and in some cases referral for bariatric surgery may be considered. 80 Statins represent another potential treatment modality in severe asthma; statins have pleiotropic anti-inflammatory effects, such as a reduction of matrix-metalloproteinase in murine models of smoking-related lung disease, as well as enhanced corticosteroid sensitivity. 83 These observations indicate a potential for effect in neutrophilic asthma, which seems to be more common in obese asthma patients. Observational studies have indicated a potential beneficial effect on exacerbations and hospitalization, although smaller RCTs have not shown effects on lung function and asthma control per se, and there is at present a need for larger RCT studies with exacerbations as outcome. 83 Whether statins represent a therapeutic option specifically in obese patients also remains to be demonstrated.
A retrospective cohort study has shown that asthma patients with co-existing diabetes who are treated with metformin have a lower risk of asthma exacerbations and asthma-related hospitalizations. 84 Taken together, these observations suggest that interventions targeting obesity, metabolic syndrome, systemic inflammation and diabetes may have an effect on severe asthma, although there is a clear need to understand more about which phenotypes of severe asthma may benefit from such interventions.
OBSTRUCTIVE SLEEP APNOEA SYNDROME
OSAS is defined as repetitive episodes of apnoea during sleep, relating to upper airway obstruction, 85 which causes poor quality of sleep and daytime sleepiness, but may also aggravate asthma symptoms. 86 OSAS is associated with poor asthma control. In the SARP cohort of patients with severe asthma, patients with co-morbid OSAS reported more symptoms, higher use of SABA and lower quality of life, as well as higher exacerbations rates. 12, 62 Furthermore, OSAS appears to be more severe in asthma patients, who have lower night-time oxygen levels and more episodes of apnoea than otherwise healthy controls with OSAS. 87 OSAS is very common in severe asthma. Two studies of selected patients with severe or difficult asthma, who underwent polysomnography regardless of sleep-related symptoms, revealed signs of sleep apnoea in the majority (88-92%) in terms of increased episodes of apnoea/ hypopnoea index (AHI), 87, 88 whereas the proportion of patients with symptoms clinically suggestive of OSAS was more moderate in the SARP cohort, at 31%. 62 Similar to obesity, the association between severe asthma and OSAS is bidirectional. OSAS may induce asthma symptoms, but asthma also increases the risk of OSAS, independent of obesity. 86, 89 The mechanisms by which OSAS may impact asthma control remain speculative, but factors such as an increase in neutrophilic airway inflammation 90 or vagal stimulation of the collapsed pharynx leading to increased bronchial hyperresponsiveness have been proposed as potential mechanisms. 91 The gold standard for diagnosing OSAS is a polysomnography 92 ; but validated questionnaires such as the Epworth Sleepiness Score (ESS), STOP-BANG or the Berlin Questionnaire may be used to screen for possible OSAS. 93, 94 However, it should be noted that a significant proportion of patients with OSAS in the severe asthma population may not have classic symptoms of sleep apnoea, and may be overlooked.
In this context, as the risk of OSAS is increased in patients with nasal disease, and particularly patients with CRS have an increased risk of OSAS, 95 screening for OSAS may be particularly relevant in patients with nasal symptoms, as well as in overweight patients.
Treatment of OSAS with CPAP improves asthma control. 96 Short-term CPAP treatment has been demonstrated to reduce airway hyperresponsiveness in asthma already after 7 days. 97 More recently, an unblinded cohort study of 99 asthma patients with OSAS assessed before and after 6 months of CPAP treatment showed an improvement in symptom scores, exacerbation rates and lung function. 96 Overall, OSAS appears to be a common and modifiable risk factor for poor asthma control in severe asthma, and screening for OSAS should be performed routinely in all patients with severe, poorly controlled asthma.
GASTROESOPHAGEAL REFLUX DISEASE
GERD is defined as symptoms or complications relating to reflux of stomach contents into the oesophagus. Most patients experience dyspepsia such as heartburn, but a proportion of patients are asymptomatic. 98 GERD is common in asthma, and particularly so in severe asthma, with reported prevalence rates from 17% to 74%. 10, 23, 63, 99 Additionally, a proportion of patients may have silent reflux without any symptoms, such as heartburn. 50 GERD is associated with poor symptom control 100 and has furthermore been identified as a risk factor for exacerbations in severe asthma.
12,13 Additionally, as described above, reflux may trigger VCD, and induce symptoms relating to laryngeal dysfunction, which may mimic asthma symptoms. Conversely, asthma medications may induce or aggravate GERD, thus creating a potential vicious circle. 7 Proposed mechanisms of how GERD may trigger asthma are micro-aspiration, acid stimulation of the oesophagus and vagal nerve stimulation, although evidence is somewhat conflicting. 101 The diagnosis of GERD may be difficult as both pH monitoring and endoscopy have limited sensitivity. 102 Hence, a trial of treatment with PPI is recommended as the initial diagnostic step in symptomatic patients. 102 The effect on asthma-related outcomes of treating GERD is controversial. While there is no convincing effect on objective outcomes such as lung function and airway hyperresponsiveness, some studies show effect on symptoms, quality of life and exacerbations. 103, 104 This may suggest that symptoms triggered by GERD are mimics of asthma symptoms, rather than exacerbating airway inflammation or airway hyperresponsiveness. There are no predictors of the effect of treating GERD in the individual patient. 103 Acid suppression should be considered in patients with significant symptoms of GERD, with careful monitoring of the effect, whereas asymptomatic patients are generally unlikely to benefit from a trial of acid suppression.
BRONCHIECTASIS
Bronchiectasis is defined radiologically as chronic enlargement of the airways, and clinically may be associated with symptoms of chronic cough and expectoration, as well as a tendency to infections, 105 although a proportion of patients with bronchiectasis on HRCT are asymptomatic.
Bronchiectasis may develop as a consequence of a number of chronic lung diseases. 106 The prevalence of bronchiectasis in patients with severe asthma is relatively high, with 25-40% of patients with severe asthma reported to have radiological signs of bronchiectasis 64, 65 compared with only 3% in a population of generally milder asthma. 107 Asthma patients with coexisting bronchiectasis appear to be at higher risk of asthma exacerbations and hospitalizations. 107, 108 Bronchiectasis per se may cause airway obstruction and hence contribute to obstructive airflow limitation, 65 and accordingly is also a differential diagnosis to asthma. 109 Bronchiectasis is associated with impaired mucociliary clearance as well as mucus hypersecretion, which increases the tendency to airway obstruction, but also increases the susceptibility to infections. 109 Bronchiectasis is furthermore associated with ABPA in severe asthma 66 (see below). HRCT should be considered in patients with severe asthma who have clinical signs of bronchiectasis, such as chronic cough and expectoration, or recurrent infections requiring antibiotics. The management of bronchiectasis is focused on improving airway clearance by physiotherapy, inhalation of hyperosmolar agents and exercise and by reducing airway inflammation. 110 Lowdose macrolide treatment has shown consistent effects on reducing exacerbations in patients with non-cystic fibrosis bronchiectasis. 110, 111 In severe cases, inhaled antibiotics may be considered, although the evidence for the effect is somewhat controversial. 110 However, there is little evidence on whether managing bronchiectasis in severe asthma may improve asthma-related outcomes, but considering the high prevalence of this co-morbidity, there appears to be a need for studies on this topic.
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
ABPA is a hypersensitivity reaction to Aspergillus fumigatus, mainly observed as a complication of asthma and cystic fibrosis.
66 Although a relatively rare condition, with prevalence rates of only 1-2% in persistent asthma, 66 ABPA may have significant impact on asthma control, and should be included in the co-morbidities assessed in difficult asthma. Asthma patients with ABPA typically report symptoms of chronic mucus hypersecretion, and ABPA may thus contribute to poor asthma control, but is also a risk factor for accelerated loss of lung function. 66 Conversely, lung function impairment has been identified as a risk factor for developing ABPA. 112 Furthermore, late onset of asthma and, perhaps surprisingly, absence of coexisting atopic disorders such as atopic eczema and allergic rhinitis is associated with an increased risk of subsequent ABPA development 112 The most recent criteria for a diagnosis of ABPA in asthma is based on five criteria function, (ii) immediate Aspergillus species skin test reactivity, (iii) total serum IgE level of 1000 ng/mL (416 IU/mL) or greater, (iv) increased Aspergillus species-specific IgE and IgG antibodies and (v) chest radiographic infiltrates. Additional criteria might include peripheral blood eosinophilia, Aspergillus species serum precipitating antibodies, central bronchiectasis and Aspergillus species-containing mucus plugs'. 113 Based on the presence of bronchiectasis, patients may be divided into ABPA-S (ABPA-seropositive) or ABPA-CB (ABPA-central bronchiectasis). It should be noted that some patients are sensitized to other fungi than Aspergillus (allergic bronchopulmonary mycosis (ABPM)), however specific IgE to these fungi may be difficult to detect. 66 Sensitization to Aspergillus in severe asthma in the absence of other features of ABPA has been termed severe asthma with fungal sensitization (SAFS). 113 The impact and management of this condition is somewhat debated. Although an early trial with itraconazole demonstrated an effect on asthma-related quality of life, 114 a subsequent study with voriconazole was negative. 115 Hence, the ERS/ATS guidelines recommend that SAFS without other characteristics of ABPA should not be treated with anti-fungals, as a result of an overall negative risk-benefit ratio relating to the potential side effects and interactions associated with anti-fungals. 8 The management of ABPA aims to reduce airway inflammation, and the key treatment is systemic corticosteroids, typically given over months, with an initial dose of 0.5 mg/kg of prednisone, tapered over 6-8 weeks, but in some cases continued over longer periods. 66 Anti-fungals may be given in combination with prednisone, with itraconazole (200 mg bd) as the most recommended choice, but voriconazole and posaconazole have also shown a clinical effect in ABPA. 66 In some cases, monoclonal antibody treatment with omalizumab has been shown to be effective in ABPA patients 116 and may be considered in patients who have had a successful reduction in total IgE after initial treatment.
EOSINOPHILIC GRANULOMATOUS WITH POLYANGIITIS
EGPA (previously termed Churg-Strauss) is a necrotizing small to medium vessel vasculitis, characterized by eosinophilic infiltrations of various organs, for example the heart, kidneys, nervous system, gastrointestinal tract, skin and muscles. 117 As EGPA typically develops through a prodromal stage of severe asthma, it may be perceived as a potential complication in severe eosinophilic asthma. 118 Given the high mortality of untreated EGPA, clinicians treating severe asthma should have a high level of diagnostic awareness for signs of EGPA, such as increasing blood eosinophils and extrapulmonary organ manifestations. 118 Diagnostic criteria for EGPA include the presence of at least four of the following criteria: asthma, paranasal sinusitis, blood eosinophils > 10%, pulmonary infiltrates which may be transient, histological evidence of eosinophilic vasculitis and mononeuritis multiplex or peripheral neuropathy. 119 Serological testing may aid in the diagnosis; however, only approximately 40% of patients have an elevated ANCA, most commonly p-ANCA against myeloperoxidase.
Treatment of EGPA requires systemic corticosteroids, usually in combination with immunosuppressants (e.g. cyclophosphamide, methotrexate or azathioprine). 120 Furthermore, some patients may benefit from treatment with monoclonal antibodies such as Rituximab and anti-IL-5 in particular appears to be a promising future treatment option for these patients.
120
CONCLUSIONS
Co-morbidities are common in severe asthma, and may contribute significantly to poor symptom control and exacerbations. Systematically assessing patients with potentially severe asthma for co-morbidities is important in order to achieve treatment results, but also to differentiate between patients with true, severe refractory asthma, and patients in whom poor symptom control is caused by co-morbidities. Assessing and managing co-morbidities in severe asthma require a multidisciplinary approach, preferentially in the setting of a dedicated severe asthma clinic.
At present, more evidence from well-designed, randomized intervention trials is required to evaluate the effect of managing specific co-morbidities in severe asthma, particularly with regards to the nonpharmacological interventions for DB and VCD, as well as anxiety and depression. Finally, there is a clear need for a further clarification of the links between specific co-morbidities, and different phenotypes of severe asthma. This might improve both our understanding of severe asthma phenotypes per se, but could also aid in the everyday assessment and management of this patient group.
